{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:18:47Z","timestamp":1792682327953,"version":"4.5.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.antiviral.2013.03.014","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T07:21:32Z","timestamp":1363936892000},"page":"174-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":325,"title":["Influenza virus resistance to neuraminidase inhibitors"],"prefix":"10.1016","volume":"98","author":[{"given":"M\u00e9lanie","family":"Samson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Pizzorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacine","family":"Abed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Boivin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2013.03.014_b0005","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/135965350601100804","article-title":"Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds","volume":"11","author":"Abed","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2013.03.014_b0010","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1086\/595736","article-title":"A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A\/H3N2 virus","volume":"199","author":"Abed","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0015","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/infdis\/jir610","article-title":"Parenteral peramivir treatment for oseltamivir-resistant 2009 pandemic influenza A H1N1 viruses","volume":"204","author":"Abed","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0020","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1086\/344237","article-title":"Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene","volume":"186","author":"Abed","year":"2002","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0025","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/135965350400900404","article-title":"A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A\/H1N1 virus","volume":"9","author":"Abed","year":"2004","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2013.03.014_b0030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.antiviral.2007.08.008","article-title":"Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes","volume":"77","author":"Abed","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.03.014_b0035","doi-asserted-by":"crossref","first-page":"e1002431","DOI":"10.1371\/journal.ppat.1002431","article-title":"Role of permissive neuraminidase mutations in influenza A\/Brisbane\/59\/2007-like (H1N1) viruses","volume":"7","author":"Abed","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2013.03.014_b0040","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/135965350701200S04.1","article-title":"Influenza virus susceptibility and resistance to oseltamivir","volume":"12","author":"Aoki","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2013.03.014_b0045","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1021\/jm0002679","article-title":"BCX-1812-a novel, highly potent, orally active and selective influenza neuraminidase inhibitor through structure-based drug design","volume":"43","author":"Babu","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2013.03.014_b0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/prot.340020205","article-title":"Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus","volume":"2","author":"Baker","year":"1987","journal-title":"Proteins"},{"key":"10.1016\/j.antiviral.2013.03.014_b0055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2005.10.002","article-title":"Anti-influenza virus activity of peramivir in mice with single intramuscular injection","volume":"69","author":"Bantia","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.03.014_b0060","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1128\/AAC.45.4.1162-1167.2001","article-title":"Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir","volume":"45","author":"Bantia","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0065","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1177\/135965350501000805","article-title":"Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment","volume":"10","author":"Barroso","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2013.03.014_b0070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0166-3542(03)00011-1","article-title":"A point mutation in influenza B confers resistance to peramivir and loss of slow binding","volume":"59","author":"Baum","year":"2003","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.03.014_b0075","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.antiviral.2006.10.012","article-title":"Characterization of drug-resistant recombinant influenza A\/H1N1 viruses selected in vitro with peramivir and zanamivir","volume":"74","author":"Baz","year":"2007","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.03.014_b0080","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/508777","article-title":"Characterization of multidrug-resistant influenza A\/H3N2 viruses shed during 1year by an immunocompromised child","volume":"43","author":"Baz","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0085","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1056\/NEJMc0910060","article-title":"Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis","volume":"361","author":"Baz","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.03.014_b0090","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1086\/650464","article-title":"Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses","volume":"201","author":"Baz","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0095","unstructured":"Biota Holdings Ltd., 2009a. LANI Phase III clinical trials in Asia prove successful. <http:\/\/www.biota.com.au\/uploaded\/154\/1021542_25laniphaseiiiclinicaltri.pdf> [accessed November 2012]."},{"key":"10.1016\/j.antiviral.2013.03.014_b0100","unstructured":"Biota Holdings Ltd., 2009b. Phase III trial with CS-8958 for flu prevention underway. <http:\/\/www.biota.com.au\/uploaded\/154\/1021585_54cs8958phaseiiipreventio.pdf> [accessed November 2012]."},{"key":"10.1016\/j.antiviral.2013.03.014_b0105","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMp0910479","article-title":"The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza","volume":"361","author":"Birnkrant","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.03.014_b0110","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1126\/science.1187816","article-title":"Permissive secondary mutations enable the evolution of influenza oseltamivir resistance","volume":"328","author":"Bloom","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2013.03.014_b0115","doi-asserted-by":"crossref","first-page":"e22201","DOI":"10.1371\/journal.pone.0022201","article-title":"A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase","volume":"6","author":"Bloom","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2013.03.014_b0120","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.antiviral.2008.05.012","article-title":"Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice","volume":"80","author":"Boltz","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.03.014_b0125","doi-asserted-by":"crossref","first-page":"94729","DOI":"10.1128\/AAC.00200-12","article-title":"Safety, tolerability and pharmacokinetics of intravenous oseltamivir: single and multiple dose phase I studies in healthy volunteers","volume":"56","author":"Brennan","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/j.1460-2075.1992.tb05026.x","article-title":"The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid","volume":"11","author":"Burmeister","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2013.03.014_b0135","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1128\/AAC.43.7.1616","article-title":"Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection","volume":"43","author":"Calfee","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0166-3542(01)00215-7","article-title":"Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo","volume":"54","author":"Carr","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.03.014_b0145","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/INF.0b013e3181ff863b","article-title":"Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer","volume":"30","author":"Carr","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.03.014_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199936001-00001","article-title":"Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers","volume":"36","author":"Cass","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.antiviral.2013.03.014_b0155","first-page":"44","article-title":"High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents-United States, 2005\u201306 influenza season","volume":"55","author":"CDC","year":"2006","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.antiviral.2013.03.014_b0160","first-page":"969","article-title":"Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina, 2009","volume":"58","author":"CDC","year":"2009","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.antiviral.2013.03.014_b0165","first-page":"893","article-title":"Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients \u2013 Seattle, Washington, 2009","volume":"58","author":"CDC","year":"2009","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.antiviral.2013.03.014_b0170","first-page":"115","article-title":"Update: influenza activity \u2013 United States, September 28, 2008\u2013January 31, 2009","volume":"58","author":"CDC","year":"2009","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.antiviral.2013.03.014_b0175","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/0091270012440280","article-title":"Pharmacokinetic properties of anti-influenza neuraminidase inhibitors","volume":"53","author":"Chairat","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2013.03.014_b0180","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/infdis\/jiq124","article-title":"Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients-North Carolina, 2009","volume":"203","author":"Chen","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0185","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1016\/j.vaccine.2009.07.017","article-title":"Structural basis for oseltamivir resistance of influenza viruses","volume":"27","author":"Collins","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2013.03.014_b0190","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/nature06956","article-title":"Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants","volume":"453","author":"Collins","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.014_b0195","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/JVI.67.6.2972-2980.1993","article-title":"Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase","volume":"67","author":"Colman","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.014_b0200","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/303041a0","article-title":"Structure of the catalytic and antigenic sites in influenza virus neuraminidase","volume":"303","author":"Colman","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.014_b0205","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3201\/eid1603.091321","article-title":"Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs","volume":"16","author":"Dapat","year":"2010","journal-title":"Emerg. Infect. Dis."},{"issue":"Suppl. 2","key":"10.1016\/j.antiviral.2013.03.014_b0210","doi-asserted-by":"crossref","first-page":"ii5","DOI":"10.1093\/jac\/dkq015","article-title":"Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations","volume":"65","author":"Davies","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0215","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa054512","article-title":"Oseltamivir resistance during treatment of influenza A (H5N1) infection","volume":"353","author":"de Jong","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.03.014_b0220","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jama.2009.294","article-title":"Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States","volume":"301","author":"Dharan","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2013.03.014_b0225","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/bmj.322.7286.577","article-title":"Comparison of elderly people\u2019s technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial","volume":"322","author":"Diggory","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.antiviral.2013.03.014_b0230","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2165\/00002018-200326110-00004","article-title":"Safety and pharmacology of oseltamivir in clinical use","volume":"26","author":"Dutkowski","year":"2003","journal-title":"Drug Safety"},{"key":"10.1016\/j.antiviral.2013.03.014_b0235","doi-asserted-by":"crossref","first-page":"e1000362","DOI":"10.1371\/journal.pmed.1000362","article-title":"Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial","volume":"7","author":"Duval","year":"2010","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2013.03.014_b0240","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jiph.2009.04.004","article-title":"Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt","volume":"2","author":"Earhart","year":"2009","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.antiviral.2013.03.014_b0245","first-page":"1472","article-title":"Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child","volume":"17","author":"Eshaghi","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0250","unstructured":"FDA, 2009. Food and drug administration emergency use authorization fact sheet for heath care providers. <http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM187811.pdf> [accessed November 2012]."},{"key":"10.1016\/j.antiviral.2013.03.014_b0255","unstructured":"FDA, 2011. Relenza (zanamivir) information. <http:\/\/www.fda.gov\/drugs\/drugsafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm183783.htm> [accessed November 2012]."},{"key":"10.1016\/j.antiviral.2013.03.014_b0260","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.antiviral.2005.07.004","article-title":"Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice","volume":"68","author":"Ferraris","year":"2005","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.03.014_b0265","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bbrc.2012.10.095","article-title":"A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reducedsusceptibility to multiple neuraminidase-inhibitor drugs","volume":"429","author":"Fujisaki","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2013.03.014_b0270","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0275","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0280","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.03.014_b0285","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/095632020601700502","article-title":"Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice","volume":"17","author":"Galabov","year":"2006","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0290","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1128\/JVI.06085-11","article-title":"Amino acid changes in hemagglutinin contribute to the replication of oseltamivir-resistant H1N1 influenza viruses","volume":"86","author":"Ginting","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.014_b0295","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1128\/AAC.48.12.4855-4863.2004","article-title":"Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells","volume":"48","author":"Govorkova","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0300","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3201\/eid1702.101724","article-title":"Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States","volume":"17","author":"Graitcer","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0305","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.virusres.2004.02.034","article-title":"Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors","volume":"103","author":"Gubareva","year":"2004","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2013.03.014_b0310","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1086\/314440","article-title":"Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus","volume":"178","author":"Gubareva","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0315","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1086\/651604","article-title":"Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus","volume":"50","author":"H\u00e4rter","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0320","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3201\/eid1502.081031","article-title":"Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007\u201308","volume":"15","author":"Hauge","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0325","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1128\/AAC.25.1.53","article-title":"Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro","volume":"25","author":"Hayden","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0330","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003088-199937060-00003","article-title":"Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64\u20130802","volume":"37","author":"He","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.antiviral.2013.03.014_b0335","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1128\/JCM.00682-12","article-title":"Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient","volume":"50","author":"Higgins","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2013.03.014_b0340","unstructured":"HPA, 2009. Health Protection Agency. HPA statement on possible transmission of oseltamivir resistant pandemic influenza A(H1N1). Technical report, UK Government. <http:\/\/www.hpa.org.uk\/webw\/HPAweb&HPAwebStandard\/HPAweb_C\/1258560561316?p=1231252394302> [accessed November 2012]."},{"key":"10.1016\/j.antiviral.2013.03.014_b0345","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1473-3099(11)70318-8","article-title":"Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives","volume":"12","author":"Hurt","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0350","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1056\/NEJMc1111078","article-title":"Community transmission of oseltamivir-resistant a(h1n1)pdm09 influenza","volume":"365","author":"Hurt","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.03.014_b0355","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/infdis\/jis337","article-title":"Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in australia","volume":"206","author":"Hurt","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0360","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/AAC.00334-09","article-title":"In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses","volume":"53","author":"Hurt","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0365","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1128\/JVI.01200-09","article-title":"Zanamivir-resistant influenza viruses with a novel neuraminidase mutation","volume":"83","author":"Hurt","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.014_b0370","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3201\/eid1801.111079","article-title":"Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses","volume":"18","author":"Hurt","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0375","doi-asserted-by":"crossref","first-page":"19884","DOI":"10.2807\/ese.16.23.19884-en","article-title":"Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation","volume":"16","author":"Hurt","year":"2011","journal-title":"Euro Surveill."},{"key":"10.1016\/j.antiviral.2013.03.014_b0380","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.antiviral.2010.06.009","article-title":"Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model","volume":"87","author":"Hurt","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.03.014_b0385","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/eri.11.112","article-title":"Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza","volume":"9","author":"Ikematsu","year":"2011","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.antiviral.2013.03.014_b0390","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1128\/AAC.01579-07","article-title":"Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice","volume":"52","author":"Ilyushina","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0395","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1177\/0091270009356297","article-title":"Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers","volume":"50","author":"Ishizuka","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2013.03.014_b0400","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/0091270010361914","article-title":"Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958","volume":"51","author":"Ishizuka","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2013.03.014_b0405","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/QCO.0b013e32833bc1c3","article-title":"Influenza, including the novel H1N1, in organ transplant patients","volume":"23","author":"Ison","year":"2010","journal-title":"Opin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0410","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1086\/500465","article-title":"Recovery of drug-resistant influenza virus from immunocompromised patients: a case series","volume":"193","author":"Ison","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0415","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jac\/dkh528","article-title":"Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations","volume":"55","author":"Jackson","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0420","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1086\/650176","article-title":"Fatal respiratory events caused by zanamivir nebulization","volume":"50","author":"Kiatboonsri","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0425","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1021\/jm980162u","article-title":"Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors","volume":"41","author":"Kim","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2013.03.014_b0430","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(04)16934-1","article-title":"Resistant influenza A viruses in children treated with oseltamivir: descriptive study","volume":"364","author":"Kiso","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2013.03.014_b0435","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1128\/AAC.00412-11","article-title":"Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques","volume":"55","author":"Kitano","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0440","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1128\/AAC.01718-10","article-title":"Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients","volume":"55","author":"Kohno","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0445","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1128\/AAC.00731-09","article-title":"CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract","volume":"53","author":"Koyama","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0450","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1128\/AAC.01311-09","article-title":"Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration","volume":"54","author":"Kubo","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0455","doi-asserted-by":"crossref","first-page":"19784","DOI":"10.2807\/ese.16.05.19784-en","article-title":"Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010\/11","volume":"16","author":"Lackenby","year":"2011","journal-title":"Euro Surveill."},{"key":"10.1016\/j.antiviral.2013.03.014_b0460","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/4371108a","article-title":"Avian flu: Isolation of drug-resistant H5N1 virus","volume":"437","author":"Le","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.014_b0465","doi-asserted-by":"crossref","first-page":"e37095","DOI":"10.1371\/journal.pone.0037095","article-title":"I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y","volume":"7","author":"LeGoff","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2013.03.014_b0470","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJMc0910448","article-title":"A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza","volume":"362","author":"Mai","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.03.014_b0475","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1002\/prot.21897","article-title":"Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1","volume":"71","author":"Malaisree","year":"2008","journal-title":"Proteins"},{"key":"10.1016\/j.antiviral.2013.03.014_b0480","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3201\/eid1605.091835","article-title":"Possible transmission of pandemic (HIN1) 2009 virus with oseltamivir resistance","volume":"16","author":"Mandelboim","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0485","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1128\/AAC.47.7.2264-2272.2003","article-title":"Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir","volume":"47","author":"McKimm-Breschkin","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(00)00103-0","article-title":"Resistance of influenza viruses to neuraminidase inhibitors-a review","volume":"47","author":"McKimm-Breschkin","year":"2000","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.03.014_b0495","doi-asserted-by":"crossref","first-page":"20266","DOI":"10.2807\/ese.17.36.20266-en","article-title":"Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012","volume":"17","author":"Meijer","year":"2012","journal-title":"Euro Surveill."},{"key":"10.1016\/j.antiviral.2013.03.014_b0500","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3201\/eid1504.081280","article-title":"Oseltamivir-resistant influenza virus A (H1N1), Europe 2007\u201308 season","volume":"15","author":"Meijer","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0505","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1086\/651605","article-title":"Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts","volume":"50","author":"Memoli","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0510","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1086\/651610","article-title":"Rapid selection of a transmissible multidrug-resistant influenza A\/H3N2 virus in an immunocompromised host","volume":"201","author":"Memoli","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0515","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1128\/AAC.42.3.640","article-title":"Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection","volume":"42","author":"Mendel","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0520","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1128\/AAC.49.11.4515-4520.2005","article-title":"Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors","volume":"49","author":"Mishin","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0525","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1128\/AAC.01339-05","article-title":"Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use","volume":"50","author":"Monto","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0530","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1086\/656439","article-title":"Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y\/I223R mutation from a child after prolonged treatment with oseltamivir","volume":"51","author":"Nguyen","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0535","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.antiviral.2012.01.006","article-title":"Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States","volume":"93","author":"Nguyen","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.03.014_b0540","doi-asserted-by":"crossref","first-page":"e9332","DOI":"10.1371\/journal.pone.0009332","article-title":"Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro","volume":"5","author":"Nguyen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2013.03.014_b0545","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1128\/AAC.00476-09","article-title":"Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro","volume":"53","author":"Nguyen","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0550","doi-asserted-by":"crossref","first-page":"e31006","DOI":"10.1371\/journal.pone.0031006","article-title":"Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses","volume":"7","author":"Nguyen","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2013.03.014_b0555","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.antiviral.2009.11.005","article-title":"Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses","volume":"85","author":"Okomo-Adhiambo","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.03.014_b0560","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1128\/AAC.44.7.1974-1976.2000","article-title":"Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation","volume":"44","author":"Peng","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0565","unstructured":"PHAC, 2011. Public Health Agency of Canada. Fluwatch 2011, weeks 33 and 34. Technical report, Government of Canada. <http:\/\/www.phac-aspc.gc.ca\/fluwatch\/10-11\/w34_11\/index-eng.php> [accessed November 2012]."},{"key":"10.1016\/j.antiviral.2013.03.014_b0570","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1055\/s-0031-1283281","article-title":"Influenza drug resistance","volume":"32","author":"Pizzorno","year":"2011","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.antiviral.2013.03.014_b0575","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1128\/AAC.05994-11","article-title":"Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus","volume":"56","author":"Pizzorno","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0580","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/infdis\/jiq010","article-title":"Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors","volume":"203","author":"Pizzorno","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0585","doi-asserted-by":"crossref","first-page":"e1000103","DOI":"10.1371\/journal.ppat.1000103","article-title":"Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir","volume":"4","author":"Rameix-Welti","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2013.03.014_b0590","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jcv.2011.05.019","article-title":"Emerging oseltamivir resistance in seasonal and pandemic influenza A\/H1N1","volume":"52","author":"Renaud","year":"2011","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2013.03.014_b0595","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1399-3062.2010.00582.x","article-title":"Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir","volume":"12","author":"Renaud","year":"2010","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0600","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1586\/eri.11.174","article-title":"Peramivir for the treatment of influenza","volume":"10","author":"Shetty","year":"2012","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.antiviral.2013.03.014_b0605","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.00555-08","article-title":"Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008","volume":"52","author":"Sheu","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0610","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1128\/AAC.45.3.749-757.2001","article-title":"In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-270201","volume":"45","author":"Sidwell","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0615","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.3201\/eid1711.110787","article-title":"Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010\u201311","volume":"17","author":"Sleeman","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0620","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000057668","article-title":"Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin","volume":"48","author":"Smee","year":"2002","journal-title":"Chemotherapy"},{"key":"10.1016\/j.antiviral.2013.03.014_b0625","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1128\/AAC.31.8.1285","article-title":"Oral ribavirin treatment of influenza A and B","volume":"31","author":"Stein","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0630","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3201\/eid1802.111466","article-title":"Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010\u201311","volume":"18","author":"Storms","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0635","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1128\/AAC.01755-09","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection","volume":"54","author":"Sugaya","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0640","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1128\/AAC.46.4.996-1004.2002","article-title":"Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection","volume":"46","author":"Sweet","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0645","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2334-11-134","article-title":"Systematic review of influenza resistance to the neuraminidase inhibitors","volume":"11","author":"Thorlund","year":"2011","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0650","doi-asserted-by":"crossref","first-page":"e7838","DOI":"10.1371\/journal.pone.0007838","article-title":"Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein","volume":"4","author":"Triana-Baltzer","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2013.03.014_b0655","doi-asserted-by":"crossref","first-page":"e7788","DOI":"10.1371\/journal.pone.0007788","article-title":"Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein","volume":"4","author":"Triana-Baltzer","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2013.03.014_b0660","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJMc1003749","article-title":"Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus","volume":"363","author":"van der Vries","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.03.014_b0665","doi-asserted-by":"crossref","first-page":"e1002276","DOI":"10.1371\/journal.ppat.1002276","article-title":"Multidrug resistant 2009 A\/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets","volume":"7","author":"van der Vries","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2013.03.014_b0670","doi-asserted-by":"crossref","first-page":"e1002249","DOI":"10.1371\/journal.ppat.1002249","article-title":"Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition","volume":"7","author":"Vavricka","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2013.03.014_b0675","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.antiviral.2012.12.013","article-title":"Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir","volume":"97","author":"Wang","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.03.014_b0680","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1128\/AAC.46.12.3809-3816.2002","article-title":"Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir","volume":"46","author":"Wang","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.03.014_b0685","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dki018","article-title":"Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic","volume":"55","author":"Ward","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0690","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1086\/656802","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial","volume":"51","author":"Watanabe","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.014_b0695","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJM200302273480923","article-title":"Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient","volume":"348","author":"Weinstock","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.03.014_b0700","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-200102000-00002","article-title":"Oral oseltamivir treatment of influenza in children","volume":"20","author":"Whitley","year":"2001","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2013.03.014_b0705","unstructured":"WHO, a. Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: neuraminidase inhibitor (NAI). <http:\/\/www.who.int\/influenza\/gisrs_laboratory\/antiviral_susceptibility\/nai_overview\/en\/index.html> [accessed November 2012]."},{"key":"10.1016\/j.antiviral.2013.03.014_b0710","unstructured":"WHO, b. Health topic, influenza. <http:\/\/www.who.int\/topics\/influenza\/en\/> [accessed November 2012]."},{"key":"10.1016\/j.antiviral.2013.03.014_b0715","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1128\/AAC.00333-08","article-title":"CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity","volume":"53","author":"Yamashita","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0720","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1128\/AAC.49.10.4075-4084.2005","article-title":"Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility","volume":"49","author":"Yen","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.014_b0725","doi-asserted-by":"crossref","first-page":"8787","DOI":"10.1128\/JVI.00477-06","article-title":"Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses","volume":"80","author":"Yen","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.014_b0730","unstructured":"Yoshida, R., Kodama, M., Kobayashi, M., Kitano, M., Sato, A., Yamano, Y., 2009. Therapeutic effect of peramivir (S-021812, BCX-1812) after single intravenous treatment of mice infected with influenza A and B viruses. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC. Abstr. V-1065, 67."},{"key":"10.1016\/j.antiviral.2013.03.014_b0735","unstructured":"Yoshida, R., Kohno, S., Kida, H., Sugaya, N., 2011. Neuraminidase sequence analysis and susceptibilities to neuraminidase (NA) inhibitors of influenza virus isolated from peramivir clinical studies. International Union of Microbiological Societies Congress, Sapporo, Japan. 2011 Sept 11\u201316."},{"key":"10.1016\/j.antiviral.2013.03.014_b0740","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.virol.2007.12.029","article-title":"Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A\/Vietnam\/1203\/04 (H5N1)","volume":"374","author":"Yun","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2013.03.014_b0745","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/jac\/dkl321","article-title":"Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro","volume":"58","author":"Z\u00fcrcher","year":"2006","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213000685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213000685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T12:24:22Z","timestamp":1688127862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354213000685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":149,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0166354213000685"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.03.014","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influenza virus resistance to neuraminidase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}